Clinical Trial

Microdosing LSD in Women With Premenstrual Disorders

Study acronym: L4Her
Not Yet Recruiting
View on ClinicalTrials.gov →
Summary
The investigators aim to investigate the role of the serotonin 2A receptor in women with premenstrual disorders. This study uses a double-blind, randomized, controlled design with 3 arms: Intervention 1: 10 micg LSD for \~10 days during the late luteal phase (for 3 cycles) Intervention 2: 10 micg LSD every other day for \~10 days during the late luteal phase (for 3 cycles) Control intervention: Placebo for \~10 days during the late luteal phase (for 3 cycles) Each participant will be treated in only one arm. The study employs a parallel design with three treatment arms and consists of a two-cycle observational phase followed by a three-cycle treatment phase.
Trial Details
NCT Number NCT07189299
Lead Sponsor Friederike Holze
Conditions PMS, PMDD
Enrollment 150 participants
Start Date 2025-10-01
Primary Completion 2029-11-01 (estimated)
Study Completion 2030-01-01 (estimated)
Updated on ClinicalTrials.gov 2025-09-23